Preoperative FOLFOX Appears Noninferior Vs CRT in Rectal Cancer
June 4th 2023“We think that we can successfully de-escalate treatment of rectal cancer and achieve the same high cure rates [and] keep patients disease free, with less long-term toxicity and effects,” lead author Deb Schrag, MD, FASCO, MPH, said.
Tanios S. Bekaii-Saab, MD, on Potential of Dual Targeting to Transform Treatment of HER2+ CRC
August 2nd 2022At 2022 ASCO, Tanios S. Bekaii-Saab, MD, reviews the MOUNTAINEER trial of trastuzumab plus tucatinib for HER2-positive metastatic colorectal cancer and foreshadows how an approved regimen may help improve outcomes in this patient population.